Home Companies 858 Therapeutics COMPANY
Clinical Phase 2
Keywords: oncology Breast Cancer Ovarian Cancer Prostate Cancer Epithelial Ovarian Cancer BRCA2 Mutation ER+ Breast Cancer Castrate Resistant Prostate Cancer BRCA1 Mutation BRCA Mutation Endometrial Cancer Colorectal Cancer Gastric Cancer ETX-19477 Show all 14 keywords
Location: San Diego, CA · source · Oct 13, 2026
Profile checked Oct 10, 2026
At a glance HQ San Diego, CA source Stage Clinical Phase 2 Latest trial Phase 1/Phase 2: A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (May 13, 2024) source Raises and deals from press releases Raise Series B · $50M · announced Sep 26, 2024 Company release ↗ Source quote Sep 26, 2024 · Company release ↗ “The latest company announcements, milestones, publications, and presentations 858 Therapeutics Announces $50 Million Series B Financing — Round led by Avidity Partners with participation from Insight Capital” Raises announced in these releases: $50M disclosed.
From the company’s own releases; this list is partial. All raises and deals
Timeline Sep 26, 2024 Raise Series B · $50M source ↗ May 13, 2024 Trial start Phase 1/Phase 2: A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies source ↗ Upcoming milestones 2026-12 (ESTIMATED) · Phase 1/Phase 2 · A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies · NCT06395519 Estimated primary completion per ClinicalTrials.gov. Dates move.
Clinical trials (lead sponsor) 1 Record Title Phase Status Start Primary completion NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies Phase 1/Phase 2 Recruiting May 13, 2024 2026-12 (estimated)
